Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Pharmacokinetics Année : 2017

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

Anne-Laure Gagez
  • Fonction : Auteur
Kamel Laribi
Guillaume Cartron

Résumé

Rituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Rituximab pharmacokinetics shows a time dependency possibly related to changes in the target antigen amount over time. The purpose of this study was to quantify the influence of both CD20 antigenic mass and the FcγRIIIA genetic polymorphism on rituximab pharmacokinetics in CLL.

Domaines

Médicaments
Fichier principal
Vignette du fichier
tout2016.pdf (460.99 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-01769807 , version 1 (15-01-2024)

Identifiants

Citer

Mira Tout, Anne-Laure Gagez, Stéphane Lepretre, Valérie Gouilleux-Gruart, Nicolas Azzopardi, et al.. Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics, 2017, 56 (6), pp.635 - 647. ⟨10.1007/s40262-016-0470-8⟩. ⟨hal-01769807⟩
75 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More